Gotham Asset Management LLC Grows Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Gotham Asset Management LLC grew its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 35.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 337,269 shares of the medical equipment provider's stock after acquiring an additional 88,332 shares during the quarter. Gotham Asset Management LLC owned approximately 0.15% of Hologic worth $24,314,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Venturi Wealth Management LLC grew its holdings in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. Smithfield Trust Co lifted its stake in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 400 shares during the last quarter. Finally, Sound Income Strategies LLC bought a new position in shares of Hologic during the 4th quarter worth approximately $60,000. 94.73% of the stock is currently owned by institutional investors.

Hologic Price Performance

Shares of HOLX traded down $1.31 during mid-day trading on Tuesday, hitting $57.50. 255,900 shares of the company were exchanged, compared to its average volume of 2,088,655. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The company has a 50 day moving average of $59.37 and a 200-day moving average of $68.01. The stock has a market cap of $12.81 billion, a price-to-earnings ratio of 18.24, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. During the same quarter in the prior year, the company earned $1.03 EPS. Hologic's revenue was down 1.2% compared to the same quarter last year. Analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on HOLX. Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. William Blair reiterated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Royal Bank of Canada decreased their price target on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Raymond James restated an "outperform" rating and issued a $71.00 target price (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Finally, Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Twelve analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $78.58.

Insider Buying and Selling at Hologic

In related news, Director Martin D. Madaus purchased 5,445 shares of the business's stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the purchase, the director now directly owns 5,445 shares of the company's stock, valued at $300,781.80. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.88% of the stock is currently owned by corporate insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.